Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc. is positioned positively due to its focus on innovative one-time gene therapies aimed at neurodegenerative diseases, with the development of PBFT02 which may benefit from an amended trial protocol allowing for earlier intervention. The potential for accelerated regulatory approval based on biomarker endpoints could significantly shorten trial timelines and enhance the program's value proposition, provided that biomarker and clinical data show comparable results with competing therapies. Additionally, the company's operational strategy to enroll patients in Cohort 3 in parallel could expedite overall trial progress, potentially leading to a more favorable market positioning.

Bears say

Passage Bio Inc. faces significant risks that contribute to a negative outlook on its stock, particularly regarding the development of its gene therapy programs, which are still in early stages. Delays in clinical timelines, along with potential safety concerns and challenges in manufacturing capacity, could adversely affect market sentiment and lead to downward revisions of financial estimates. Additionally, the complex nature of AAV-based gene therapies increases the likelihood of unforeseen setbacks, further complicating the pathway to regulatory alignment and product commercialization.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.